Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-302 Monotherapy and Combination with Tamoxifen in Advanced Solid Tumors
NCT04433494Phase 1Unknown
- Sponsor
- TYK Medicines
- Start
- Dec 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ty-302 in solid tumor and breast cancer (3 arms), sponsored by TYK Medicines. Primary endpoints: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302 at 1 year, Dose Limiting Toxicity (DLT) of TY-302 and 6 more. Status: unknown.
02
Drugs
ty-302
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT04433494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433494.